Here’s What Drove Supernus Pharmaceuticals Stock in March 2018



SUPN stock performance

Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018. In its 2017 results announced on February 28, 2018, the company focused on developing and commercializing drugs targeted at treating central nervous system diseases. It reported a 41% year-over-year (or YoY) growth in fiscal 2017 revenues, which were about $300 million. It also reported earnings before income tax of around $100 million in 2017, which is a YoY rise of 100%. It reported robust financial performance in 2017 despite an increase in research and development investments attributable to the eight ongoing Phase 3 studies for investigational drugs SPN-810 and SPN-812, as well as operating expenses attributable to the expansion of its sales force by 40 people.

On April 4, 2018, Supernus Pharmaceuticals was trading 53% above its 52-week low of $29.55 and 9.6% below its 52-week high of $50.05.

Its peers AstraZeneca (AZN), Jazz Pharmaceuticals (JAZZ), and Eli Lilly (LLY) are expected to report revenues of $22.6 billion, $1.9 billion, and $ 23.4 billion, respectively, in 2018.

Article continues below advertisement

Analyst recommendations for Supernus in April 2018

Of the nine analysts tracking Supernus Pharmaceuticals in April 2018, three have recommended a “strong buy” for the stock, four have recommended a “buy,” and one has recommended a “hold.” On April 6, 2018, Supernus Pharmaceuticals had a consensus 12-month target price of $53.67, which is 18.5% higher than its current price.


More From Market Realist